Kuwait Pneumococcal Vaccine Market Size & Outlook
Kuwait pneumococcal vaccine market, 2018-2030 (US$M)
Related Markets
Kuwait pneumococcal vaccine market highlights
- The Kuwait pneumococcal vaccine market generated a revenue of USD 1.6 million in 2023 and is expected to reach USD 5.6 million by 2030.
- The Kuwait market is expected to grow at a CAGR of 19.5% from 2024 to 2030.
- In terms of segment, pneumococcal conjugate vaccine was the largest revenue generating vaccine type in 2023.
- Pneumococcal Conjugate Vaccine is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Pneumococcal vaccine market data book summary
| Market revenue in 2023 | USD 1.6 million |
| Market revenue in 2030 | USD 5.6 million |
| Growth rate | 19.5% (CAGR from 2023 to 2030) |
| Largest segment | Pneumococcal conjugate vaccine |
| Fastest growing segment | Pneumococcal Conjugate Vaccine |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Walvax Biotechnology, Beijing Minhai Biotechnology Co. |
Other key industry trends
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa pneumococcal vaccine market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 37.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pneumococcal Vaccine Market Scope
Pneumococcal Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Kuwait pneumococcal vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 93.75% in 2023. Horizon Databook has segmented the Kuwait pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
In Kuwait, the market for pneumococcal vaccines is influenced by various factors. The prevalence of pneumococcal diseases, including pneumonia and meningitis, affects the demand for vaccines. Government vaccination programs and policies also play a crucial role in shaping the market scenario.
The Kuwaiti government emphasizes public health initiatives, including immunization programs, to protect the population from preventable diseases. This drives the demand for pneumococcal vaccines as part of routine immunization schedules.
In terms of competition, multinational pharmaceutical companies dominate the pneumococcal vaccine market in Kuwait. These companies have established distribution channels and brand recognition, giving them a competitive advantage.
Reasons to subscribe to Kuwait pneumococcal vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Kuwait pneumococcal vaccine market databook
-
Our clientele includes a mix of pneumococcal vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait pneumococcal vaccine market, including forecasts for subscribers. This country databook contains high-level insights into Kuwait pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Kuwait pneumococcal vaccine market size, by vaccine type, 2018-2030 (US$M)
Kuwait Pneumococcal Vaccine Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
